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ABSTRACT
Over the past three decades, penicillin-resistant pneumococci have emerged worldwide. In addition, penicillin-
resistant strains have also decreased susceptibility to other /Mactams (including cephalosporins) and these
strains are often resistant to other antibiotic groups, making the treatment options much more difficult. Nev-
ertheless, the present in vitro definitions of resistance to penicillin and cephalosporins in pneumococci could
not be appropriated for all types of pneumococcal infections. Thus, current levels of resistance to penicillin
and cephalosporin seem to have little, if any, clinical relevance in nonmeningeal infections {e.g., pneumonia
or bacteremia). On the contrary, numerous clinical failures have been reported in patients with pneumococ-
cal meningitis caused by strains with MICs S 0.12 fig/ml, and penicillin should never be used in pneumo-
coccal meningitis except when the strain is known to be fully susceptible to this drug. Today, therapy for
pneumococcal meningitis should mainly be selected on the basis of susceptibility to cephalosporins, and most
patients may currently be treated with high-dose cefotaxime (±) vancomycin, depending on the levels of re-
sistance in the patient's geographic area. In this review, we present a practical approach, based on current
levels of antibiotic resistance, for treating the most prevalent pneumococcal infections. However, it should be
emphasized that the most appropriate antibiotic therapy for infections caused by resistant pneumococci re-
mains controversial, and comparative, randomized studies are urgently needed to clarify the best antibiotic
therapy for these infections.
INTRODUCTION
Pneumococcal infections are very prevalent worldwide,and Streptococcus pneumoniae is a major cause of pneu-
monia, meningitis, acute otitis media, and acute sinusitis.10,70
During the past 30 years, pneumococci have developed resis-
tance to several antimicrobial agents, including tetracycline,
penicillin, trimethoprim-sulfamethoxazole, chloramphenicol,
erythromycin, cephalosporins, and other drugs.5,12,17'29,54,61
But, in terms of therapy, the real problem has been the devel-
opment of resistance to penicillin. This is because penicillin
was the time-honored treatment for pneumococcal infections
for decades, and alternative drugs were only necessary in peni-
cillin-allergic patients.
An interesting issue is that, shortly after the introduction of
penicillin in 1940, the first strain of 5. pneumoniae with de-
creased susceptibility to penicillin was produced in the labora-
tory,28 but the first clinical isolate did not appear until more
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than 20 years later in Boston.52 In the late 1960s, pneumococ-
cal strains with moderate penicillin resistance were isolated in
Australia and New Guinea.41,42 In the 1970s, an epidemic of
high-level penicillin- and multidrug-resistant pneumococci was
detected in pédiatrie wards in South Africa.6,50 Subsequently,
resistant strains were identified in Europe, particularly in
Spain.30,57,60 Finally, in the 1980s, penicillin-resistant pneu-
mococci emerged in many countries. Today, the prevalence of
pneumococci resistant to penicillin and other antibiotics is in-
creasing worldwide.14,20,21,37,39,45,65,66
As shown in several studies, resistance rates varied with the
geographic area and age of the patient, the highest being the
rate of resistance among isolates from otitis media in chil-
dren.21,54,60,61 It is important to emphasize that antimicrobial
consumption is a major factor contributing to penicillin resis-
tance and other antibiotic resistance in pneumococci.7,13
Although antibiotic resistance is a complex phenomenon that
we do not know very well, it is important to note that resistant
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pneumococcal strains have the ability to spread rapidly through-
out the world. For example, the Spanish clone 23F and 6B have
been disseminated to other countries in Europe and to other
continents.69,82
The mechanism of resistance of pneumococci to penicillin
is due to alterations of the penicillin binding proteins (PBPs)
that have reduced their affinity for penicillin and related /3-lac-
tams.48,64,85,86 Therefore, susceptibility to other /3-lactams is
also affected and the minimal inhibitory concentrations (MICs)
of these drugs rise in parallel with those of penicillin G, al-
though with different degrees depending on the drug59,67,76,83(Table 1). Cefotaxime, ceftriaxone, cefpirome, and cefepime
are the parenteral cephalosporins that yield the lowest MICs
against penicillin-resistant strains. The MICs of carbapenems
are smaller than those of cephalosporins. Thus, imipenem is
highly active against penicillin-resistant strains, but meropenem
is slightly less active in vitro than imipenem. Amongst oral ß-
lactams, amoxicillin yields the lowest MICs against penicillin-
resistant pneumococci, and cefuroxime and cefpodoxime are
the oral cephalosporins that yield the lowest MICs, although
these are several times higher than those of amoxicillin. In ad-
dition, penicillin-resistant strains are more likely to be resistant
to other antibiotic groups such as erythromycin, tetracycline,
chloramphenicol, and trimethoprim-sulfamethoxazole.17,54,61
However, the newest quinolones (e.g., trovafloxacin, spar-
floxacin, grepafloxacin) seem to be very active compounds
against penicillin-resistant and -susceptible strains.
The current in vitro definition of penicillin resistance by S.
pneumoniae (National Committee for Clinical Laboratory Stan-
dards, NCCLS 1995) is as follows: susceptible strains (MIC S
0.06 pg/ml of penicillin G), intermediate resistance (MIC
0.12-1.0 pg/ml of penicillin G), and high-level resistance(MIC a: 2.0 pg/ml of penicillin G). However, the laboratory
definition of resistance to penicillin was established before the
clinical relevance of this level of resistance had been deter-
mined. In other words, the current in vitro definitions of peni-
Table 1. In Vitro Activity of Several Antibiotics in
952 Penicillin-Resistant Streptococcus pneumoniae3
Antibiotic MIC range MIC-50/MIC-90
aData from the Microbiology Laboratory (1990-1995),
Bellvitge Hospital, Barcelona.
•The ratio of trimethoprim-sulfamethoxazole is 1/19.
cillin resistance are open to question, particularly for those
pneumococcal strains causing nonmeningeal infections.
Although no prospective, randomized studies on the therapy of
resistant pneumococcal infections have been carried out, the pub-
lished data suggest that moderate penicillin-resistant pneumococci
causing nonmeningeal infections such as pneumonia or bac-
teremia have no therapeutic significance.11,31,33,55,74,75,80,84,91
This is because the serum concentrations achieved with peni-
cillin or related ß-lactams are several times higher than the
MICs of the strains.4 On the other hand, however, pneumo-
coccal meningitis poses a special therapeutic problem because
of the levels of penicillin achieved in the cerebrospinal fluid(CSF) are inadequate to kill penicillin-resistant pneumococci
including those with intermediate resistance,43 and several clin-
ical failures have been reported.19,34,36,78
The management of pneumococcal infections caused by re-
sistant strains has been debated in recent reviews,19'34,36,61'78 but
several important questions remain to be answered. The most im-
portant considerations in selecting empirical antibiotic therapy in
patients with a suspected pneumococcal infection are the fol-
lowing: prevalence and patterns of resistance in the patient's ge-
ographic area; site of infection (e.g., meningitis); risk factors for
penicillin-resistant strains (e.g., prior antibiotic use, young age,
day-care attendance, prior hospitalization, nosocomial infec-
tion)16,63,73,74; severity of illness and probability of death; route
of drug administration; and potential toxicity and costs.
In this review, we will discuss the treatment of the most
prevalent pneumococcal infections, focusing principally on
adult patients. The regimens proposed herein are based on the
current levels of resistance, but these recommendations may
change in the near future.
THERAPY FOR PNEUMONIA
There are several reports dealing with the response to /3-lac-
tam antibiotic therapy in penicillin-resistant pneumococcal
pneumonia or bacteremia.11,31,33,55,74,75,80,84,91
Friedland and Klugman33 carried out a prospective study of
community-acquired pneumococcal infections in 207 South
African children, most of them were treated with penicillin or
ampicillin at a standard dosage. They found that the mortality rate
was 14% in children with penicillin-resistant pneumococcal in-
fections and 11% in children with penicillin-susceptible infection.
Tan and colleagues84 reported their experience during a 3-
year period in Houston. All but 1 of 19 children with systemic
infections caused by intermediate penicillin-resistant pneumo-
cocci responded adequately to initial /3-lactam therapy (mostly
amoxicillin or cefuroxime).
Friedland31 reported a series of 108 children with bacteremic
pneumococcal infections, excluding meningitis. In children
with pneumonia who were treated with ampicillin or an equiv-
alent /3-lactam agent, 88% with penicillin-resistant infections
and 93% with penicillin-susceptible infections had improved by
day 7 of therapy.
Recently, we conducted a prospective nonintervention study
with 504 adult patients with severe pneumococcal pneumonia;
29% of them were infected with penicillin-resistant strains.75
Although the mortality rate was significantly higher in peni-
cillin-resistant than in penicillin-susceptible cases (38% vs.
Penicillin 0.12^1 1/2
Amoxicillin 0.06-4 0.5/1
Cefuroxime 1-16 2/8
Cefaclor 0.5-64 32/64
Cefixime 2-64 8/32
Cefotaxime 0.03^1 0.5/1
Ceftriaxone 0.03^t 0.5/1
Cefpirome 0.03-2 0.25/0.5
Ceftazidime 1-64 16/64
Imipenem 0.03-1 0.06/0.25
Meropenem 0.03-2 0.12/0.5
Erythromycin 0.03->128 0.12/128
Tetracycline 0.03->128 16/64Cotrimoxazoleb 0.12-16 4/8
Chloramphenicol 0.25-64 4/16
Vancomycin 0.12-1 0.25/0.5
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24%), after adjustment for other variables, the odds ratio for
mortality in patients with penicillin-resistant strains was not sta-
tistically significant. Moreover, when we compared the mor-
tality rate in patients treated with penicillin or ampicillin, there
were no statistically significant differences between patients in-
fected with penicillin-resistant and those infected with peni-
cillin-susceptible strains. Likewise, among patients treated with
cefotaxime or ceftriaxone, the mortality rate was not signifi-
cantly different in those infected with cephalosporin-resistant
strains when compared with those infected with cephalosporin-
susceptible strains. Our conclusion was that current levels of
resistance to penicillin and cephalosporins are not associated
with increased mortality in patients with severe pneumococcal
pneumonia. Thus, these antibiotics can still be used as the ther-
apy of choice for this disease.75
We suggest the following antibiotic therapy for community-
acquired pneumococcal pneumonia (Table 2).
Initial empirical therapy
This refers to the treatment for a patient with a clinical pic-
ture and radiologie findings highly suggestive of pneumococ-
cal pneumonia before the culture results are known. It should
be emphasized that in patients with clinical suspicion of pneu-
mococcal pneumonia, the diagnosis may be strongly reinforced
by demonstrating polymorphonuclear leukocytes (PMNs) and
Gram-positive cocci in pairs in the sputum.71 However, some-
times the clinical picture is not clear enough and the infection
may be caused by other pathogens. This possibility should be
taken into account in selecting empirical therapy, particularly
when the patient has severe pneumonia. Empirical therapy for
pneumococcal pneumonia should be classified according to the
severity of the infection (Table 2).
Mild-to-moderate pneumonia. Mild-to-moderate pneumonia
should be considered in a patient who is less than 65 years old
and has no co-morbid conditions; in these cases, an outpatient
treatment can be prescribed.
Amoxicillin may be the therapy of choice for patients with
mild/moderate pneumonia in whom a characteristic clinical pic-
ture of pneumococcal pneumonia is present. However, amoxi-
cillin-clavulanate may be preferred in some patients such as
those with chronic obstructive pulmonary disease (COPD) in
whom the causative organisms may be S. pneumoniae or other
common pathogens such as Haemophilus influenzae (often ß-
lactamase positive).
Alternative drugs such as cefuroxime, erythromycin, or peni-
cillin procaine should be selected according to the history of
allergy or when the oral route is not well tolerated.
In patients in whom, after a careful clinical evaluation,
his/her physician has doubts about the diagnosis of pneumo-
coccal pneumonia versus atypical pneumonia, a macrolide (e.g.,
erythromycin) should be given. However, it is important to
know that if the causative organisms is a pneumococcus resis-
tant to erythromycin the patient may not respond to this ther-
apy.68
Severe pneumonia. Patients with severe community-acquired
pneumonia should be hospitalized, and the criteria for severe
pneumonia includes (one or more): age > 65 years; serious un-
derlying conditions (e.g., COPD, diabetes, malignancies, heart
failure, chronic renal failure, splenectomy, cirrhosis, or chronic
Table 2. Suggested Antibiotic Regimens
for Pneumococcal pneumonia
1. Initial empirical therapy
Mild/moderate pneumonia
Primary Oral amoxicillin 1 g/8 hour or oral
amoxicillin-clauvulanate 1 g/8 hr
Alternative Oral cefuroxime 750 mg/8-12 hour or oral
erythromycin 500 mg/6 hr or i.m.
penicillin procaine 1.2 mU/12 hr
Severe pneumonia
Primary i.v. ceftriaxone 1-2 g/24 hr or i.v. cefotaxime
1-2 g/8 hr or i.v. amoxicillin-clavulanate
2 g/8 hr (+/—) i.v. erythromycin 1 g/6 hr
Alternative i.v. cefpirome 1-2 g/12 hr or i.v. cefepime
1-2 g/8-12 hr or i.v. imipenem 500 mg/
6 hr or i.v. meropenem 1 g/8 hr or i.v.
vancomycin 1 g/12 hr (+/—) i.v.
erythromycin 1 g/6 hr or a new quinoline
2. TheraDV when in vitro studies are known (severe Dneumonia)
i.m., Intramuscular; i.V., intravenous; MICs, minimal
inhibitory concentrations.
Dosage recommendations are approximate values for an adult
patient of 60-70 kg.
Dosage and intervals can be different in infants and children
and should be calculated according to their age and specific
conditions. In addition, pédiatrie patients may have pathogens
causing pneumonia different than those in adults and thus it
should be considered in selecting empirical antibiotic therapy.
Primary therapy is the treatment of choice suggested.
Alternative therapy should be selected according to (i) the
patterns of antibiotic resistance in the patient's geographic area
or when the culture results are known should be based on the
in vitro susceptibility studies; (ii) history of allergy; (iii)
toxicity; and (iv) costs.
alcoholism); previous pneumonia <1 year ago; altered mental
status; respiration rate > 30/min; blood pressure <90/60; tem-
perature >10PF; WBC <4000 or >30,000/mm3; Pa02 <60
mmHg (<90% O2 saturation); PaCÛ2 >50; needs mechanical
ventilation; chest X-ray >1 lobe; pleural effusion; Hct <30;
sepsis; and extrapulmonary disease (e.g., meningitis). One im-
Susceptible strains to penicillin (MICs <0.06 pg/ml)
Primary i.v. penicillin G 1 mU/4 hr or i.v. ampicillin
1 g/6hr
Alternative i.v. cefuroxime 1.5 g/8 hr or i.v.
ceftriaxone 1 g/24 hr or i.v. cefotaxime
1 g/8 hr or i.v. erythromycin 1 g/6 hr
Strains with decreased susceptibility to penicillin
penicillin MICs 0.12 to 2.0 pg/ml
Primary i.v. penicillin G 2 mU/4 hr or i.v. ampicillin
2g/6hr
Alternative i.v. ceftriaxone 1-2 g/24 hr or i.v.
cefotaxime 1-2 g/8 hr or i.v. erythromycin
1 g/6hr
Penicillin MICs &4.0 pg/ml
Primary Continue with the initial empirical therapy if
the clinical response is satisfactory
Alternative i.v. imipenem 500 mg/6 hr or i.v.
meropenem 1 g/8 hr or i.v. erythromycin
1 g/6 hr or i.v. vancomycin 1 g/12 hr or a
new quinoline
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portant clinical consideration is that in a patient with severe
pneumococcal pneumonia, the possibility of having associated
meningitis should be evaluated carefully because the treatment
options are substantially different (see treatment of meningitis).
To treat pneumococci and other common bacteria (e.g., H.
influenzae or other Gram-negative bacilli), the initial empirical
therapy for severe pneumonia should include an appropriate
cephalosporin or amoxicillin-clavulanate (Table 2). Addition-
ally, erythromycin should be added in cases in which Legionella
or another atypical pathogen cannot reasonably be ruled out.
In patients with severe underlying diseases (e.g., neutropenic
patients) in whom some fastidious organisms such as
Pseudomonas also needs to be treated, the combination of cef-
pirome or cefepime or imipenem or meropenem with eryth-
romycin should be considered. It is important to know that
ceftazidime has little activity against penicillin-resistant pneu-
mococci (Table 1).
There is little experience in treating patients with pneu-
mococcal pneumonia with vancomycin alone and this drug
has no activity against other pathogens such as Gram-nega-
tive bacilli. Thus, when vancomycin is selected for empiri-
cal therapy of severe pneumonia (e.g., allergy to /3-lactams
or in places in which a very high level cephalosporin resis-
tance has been detected) a combination with other drugs (e.g.,
aztreonam or ciprofloxacin) should be considered. Serum
vancomycin levels should be monitored in these patients. In
our opinion, and based on the current levels of antibiotic-re-
sistant pneumococci, vancomycin should not be widely used
for treating pneumonia.
The newest quinolones (e.g., trovafloxacin, sparfloxacin,
grepafloxacin) may play an important role in the empirical treat-
ment of severe pneumonia cases in the near future.
Therapy for known pneumococcal pneumonia
When culture results (e.g., positive cultures from blood,
pleural fluid, or a lower respiratory tract specimen) and in vitro
studies are known, any change in antibiotic therapy should be
based on the results of susceptibility tests and on the light of
clinical evolution of the patient.
Penicillin or ampicillin (at standard dosage) remains the ther-
apy of choice for susceptible strains. Alternative drugs (see
Table 2) may be necessary in penicillin-allergic patients.
Patients infected with strains having penicillin MICs of
0.12-2.0 pglml may respond to penicillin or ampicillin ther-
apy, although the administration of high dose (for example,
150,000-200,000 U/kg per day of penicillin G) would be pru-
dent to achieve higher serum and pulmonary levels of the drug.
It is not well known whether patients infected with strains
for which penicillin MIC s 4 pglml could respond to intra-
venous (i.v.) penicillin therapy. In these patients, consecutive
therapy should be based on the response to the initial empiri-
cal therapy and the results of the in vitro studies. In the case
that the patient is doing well with a cephalosporin or amoxi-
cillin-clavulanate, this therapy should be continued. On the con-
trary, if the clinical response is not satisfactory, other drugs such
as imipenem, meropenem, erythromycin, vancomycin, or a new
quinoline should be considered according to the results of the
in vitro studies.
THERAPY FOR MENINGITIS
Response to therapy in penicillin-resistant and cephalo-
sporin-resistant pneumococcal meningitis is different to that in
nonmeningeal infections. We believe that clinicians should have
in mind some important considerations when selecting antibi-
otic therapy for pneumococcal meningitis:(i) There have been numerous case reports of failure of
penicillin therapy in patients with pneumococcal meningitis
caused by intermediate or high-level penicillin-resistant
strains.1,6,22,24,27,38,46,47,62,72,77,79,92 Thus, because penicillin-re-
sistant strains are spread worldwide, the initial therapy for pneu-
mococcal meningitis should not be penicillin or ampicillin.(ii) Several patients with pneumococcal meningitis infected
with strains showing decreased susceptibility to cephalosporins
failed cefotaxime or ceftriaxone treatment.3,8,9,18,23,51,53,58,81 In
most of them, cefotaxime or ceftriaxone were administered at
the standard dosage for meningitis. However, some experience
in adults suggests that the administration of a higher dosage
of cefotaxime may be effective for treating patients with
cephalosporin-resistant pneumococcal meningitis, at least for
those with intermediate resistance.2,88,90
(iii) Vancomycin could be a good alternative for pneumo-
coccal meningitis caused by penicillin- and cephalosporin-re-
sistant strains. Nevertheless, the administration of vancomycin
at 30 mg/kg per day (the dosage recommended for adult pa-
tients) was associated with several failures in adult pneumo-
coccal meningitis.89 These failures could be due to the highly
variable concentrations of vancomycin achieved in the CSF, es-
pecially when dexamethasone was given concomitantly. How-
ever, we are unaware of any reported vancomycin failure in
pneumococcal meningitis in pédiatrie patients in whom van-
comycin is administered at higher dosages (60 mg/kg per
day).56(iv) In penicillin-resistant pneumococcal meningitis, chlor-
amphenicol treatment may not be appropriated. Several
penicillin-resistant pneumococci are also resistant to chlo-
ramphenicol. In addition, unsatisfactory results with chlo-
ramphenicol (despite the strains that were susceptible to this
drug based on the MICs) in penicillin-resistant pneumococ-
cal meningitis have been reported.32 These failures could be
due to a poor bactericidal activity of chloramphenicol in such
strains.32
We suggest the following antibiotic therapy for pneumo-
coccal meningitis (Table 3).
Initial empirical therapy
This terminology refers to the initial treatment for a patient
with pneumococcal meningitis (a purulent meningitis and a CSF
Gram stain showing typical Gram-positive diplococci). How-
ever, in cases with purulent meningitis and a CSF Gram stain
showing no microorganisms, several possible pathogens should
be considered in selecting the initial therapy, depending on the
clinical suspicion in each case.
In our opinion, the initial empirical therapy for pneumococ-
cal meningitis should be a cephalosporin such as cefotaxime.
However, because some strains may have decreased suscepti-
bility to these drugs, it may be prudent to suggest high-dose ce-
fotaxime for the initial therapy. Other cephalosporins such as
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Table 3. Suggested Antibiotic Regimens
for Pneumococcal meningitis
1. Initial empirical therapy
Primary i.v. cefotaxime 300-400 mg/kg per day (5-6 g/
6 hr) (maximum 24 g/day) (+/-) i.v.
vancomycin 30 mg/kg per day (1 g/12 hr) (in
children 60 mg/kg per day)
Alternative i.v. vancomycin (+/—) i.v. rifampin 900
mg/24 hr or i.v. cefotaxime (+) i.v.
rifampin
2. Therapy when in vitro studies are known
Strains susceptible to penicillin (MICs ^0.06 pg/ml)
Primary i.v. penicillin G 3-4 mU/4 hr
Alternative i.v. cefotaxime 3^1 g/6 hr or i.v.
ceftriaxone 4 g/24 hr or i.v. vancomycin(+/—) i.v. rifampin or i.v.
chloramphenicol 1 g/6 hr
Strains with decreased susceptibility to penicillin
penicillin MICs >0.12 pg/ml
Cefotaxime MICs <0.25 pg/ml
Primary i.v. cefotaxime 3-4 g/6 hr or i.v. ceftriaxone
4g/24hr
Alternative i.v. vancomycin (+/—) i.v. rifampin
Cefotaxime MICs 0.5 to 1.0 pg/ml
Primary i.v. cefotaxime 300-400 mg/kg per day(5-6 g/6 hr) (maximum 24 g/day)
Alternative i.v. vancomycin (+/—) i.v. rifampin
Cefotaxime MICs 2:2.0 pg/ml
Primary i.v. cefotaxime 300-400 mg/kg per day (5-6
g/6 hr) (+/—) i.v. vancomycin 30 mg/kg per
day (1 g/12 hr) (in children 60 mg/kg per
day)
Alternative i.v. vancomycin (+/—) i.v. rifampin (or
intrathecal vancomycin 5-20 mg/24-48 hr)
or i.v. meropenem 2 g/8 hr or i.v.
imipenem 1 g/6 hr or i.v. chloramphenicol
1 g/6hr
i.v., intravenous; MICs, minimal inhibitory concentrations;
MBCs, minimal bactericidal concentrations.
These suggested antibiotic regimens are for treating patients
with pneumococcal meningitis in regions in which penicillin-
resistant pneumococci are reported.
Dosage recommendations are approximate values for an adult
patient of 60-70 kg.
Dosage and intervals can be different in infants and children,
and should be calculated according to their age and specific
conditions. In addition, pédiatrie patients may have pathogens
causing meningitis different from those in adults and thus it
should be considered in selecting empirical antibiotic therapy,
particularly in cases of purulent meningitis with no microor-
ganisms in the CSF Gram stain.
Primary therapy is the treatment of choice suggested.
Alternative therapy should be selected according to (i) the
patterns of antibiotic resistance in the patient's geographic area
or when the culture results are known should be based on the
in vitro susceptibility studies; (ii) the pharmacokinetics of the
drugs; (iii) history of allergy; (iv) toxicity; and (v) costs.
cefpirome appear to be promising for resistant pneumococcal
meningitis.
In places where high-level cephalosporin resistance (MICs
of cefotaxime >2 /xg/ml) has been detected, cefotaxime may
be administered in combination with vancomycin. However, it
is important to have in mind some considerations regarding this
combination: (i) some studies of animals with cephalosporin-
resistant meningitis have suggested that the combination of
cephalosporin and vancomycin is more effective than either
drug alone,35 however, to our knowledge little clinical experi-
ence with this combination has been published56; (ii) even if
the combination is given, in adult patients cefotaxime should
be administered at a high-dosage regimen because vancomycin
(at the recommended dosage) may achieve insufficient CSF lev-
els89; (iii) by contrast, in children in whom vancomycin may
be administered at higher dose and this drug alone may be ef-
fective for pneumococcal meningitis, the concomitant admin-
istration of high-dose cefotaxime might be less important than
in adults, and the standard dose of cefotaxime or ceftriaxone
might be enough; (iv) vancomycin should be discontinued when
in vitro studies are known and the pneumococcus is suscepti-
ble to penicillin or cephalosporins.
An alternative regimen for the empirical therapy may be van-
comycin with or without rifampin. Vancomycin alone may be
appropriate for pédiatrie patients. However, in adults the com-
bination of vancomycin and rifampin may be more appropriate
(see comments on vancomycin dosage and levels above).
The combination of cefotaxime or ceftriaxone and rifampin
appeared to be promising. However, some in vitro studies in
the laboratory have shown an antagonistic effect between ri-
fampin and ß-lactams, although this has not been confirmed in
animal studies.87 To date, the relevance of this phenomenon in
clinical practice is not well known, although some data in chil-
dren with meningitis have suggested that this combination may
enhance CSF bactericidal activity compared with that of cef-
Table 4. Suggested Antibiotic Regimens
for Otitis Media and Sinusitis
Primary Oral amoxicillin 50-80 mg/kg per day (1 g/6—
8 hr) or oral amoxicillin-clavulanate 1 g/8 hr
Alternative Oral cefuroxime 750 mg/8-12 hr or i.m.
ceftriaxone 1 g/24 hr or oral erythromycin
500 mg/6 hr or oral clarithromycin 500
mg/12 hr or oral azithromycin 1 g/24 hr or
oral TMP-SMZ 160/800 mg/12 hr
i.m., Intramuscular; TMP-SMZ, trimethoprim-sulfameth-
oxazole.
Dosage recommendations are approximate values for adult
patients. Doses/intervals in parenthesis are those recommended
for an adult patient of 60-70 kg.
Dosage and intervals can be different in infants and children,
and should be calculated according to their age and specific
conditions.
Primary therapy is the treatment of choice suggested.
Alternative therapy should be selected according to (i) the
patterns of antibiotic resistance in the patient's geographic area
or if the culture results are known should be based on the in
vitro susceptibility studies; (ii) history of allergy; (iii) toxicity;
and (iv) costs.
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triaxone alone.56 Rifampin cannot be used as monotherapy be-
cause of the rapid development of resistance.
Therapy for known pneumococcal meningitis
When culture results (positive CSF and/or blood cultures)
and in vitro studies are known, any change in antibiotic ther-
apy should be based on the results of susceptibility tests and on
the light of clinical evolution of the patient. A control lumbar
puncture should be performed 24-36 hr after the start of an-
tibiotic therapy in all patients with resistant pneumococcal
meningitis.
Penicillin remains the therapy of choice for susceptible
strains, and alternative drugs are only necessary in penicillin al-
lergic patients.
Patients infected with strains with decreased susceptibility to
penicillin (MICs a 0.12 pglml) should not be treated with peni-
cillin. In such cases, cefotaxime or ceftriaxone, using the stan-
dard dose for meningitis, may be the therapy of choice for those
with MICs of cefotaxime s 0.25 pg/ml.
Based on the concept that to kill a pathogen the antibiotic
concentration in CSF should exceed by 8- to 10-fold the min-
imal bactericidal concentration (MBC) of the drug, it may be
prudent to suggest high-dose cefotaxime for those cases with
MICs of cefotaxime 0.5-1.0 pg/ml. This is because the cefo-
taxime MBC may be one dilution higher than the cefotaxime
MIC, and clinical failures have been reported in patients in-
fected with strains having cefotaxime MICs as small as 0.5
pg/ml who were treated with standard dose of cefotaxime or
ceftriaxone.3,8,9,18,23'51,53,58,81 Ceftriaxone administered at a
dose higher than 4 g/day is not recommended because of po-
tential side effects (e.g., biliary stones). To date, there is no ex-
perience with other drugs such as cefpirome or cefepime.
Up to now, several failures have been reported in
cephalosporin-resistant pneumococcal meningitis (MICs of ce-
fotaxime > 2 pg/ml) using standard dose of cefotaxime or cef-
triaxone.88 However, there are some reported cases with MICs
of cefotaxime of 2 pg/ml that were cured with high-dose ce-
fotaxime.2,88,90 In cases in which the pneumococcus has an MIC
of cefotaxime s 2 pg/ml and the patient is doing well with the
initial empirical therapy (e.g., high-dose cefotaxime with or
without vancomycin), this therapy should be continued. On the
other hand, if the patient has no good clinical response, an al-
ternative therapy should be considered in the light of the results
of a second lumbar puncture. These regimens may include van-
comycin with or without rifampin (or intrathecal vancomycin)
or alternatively meropenem or imipenem or chloramphenicol(based on in vitro studies), or perhaps new compounds (e.g.,
clinafloxacin).
The MICs of meropenem may be smaller than those of ce-
fotaxime in cephalosporin-resistant strains, but the doses rec-
ommended and the CSF levels achieved appear not to be very
promising.25 Although imipenem may have MICs smaller
than those of meropenem and some patients with meningitis
have been cured with this drug, the potential risk of seizures
should be taken into account. In addition, meropenem and
imipenem may produce hypersensitivity reactions in /31ac-
tam-allergic patients. In the case that chloramphenicol is se-
lected as an alternative therapy, MBCs determinations should
be performed.32
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THERAPY FOR OTITIS MEDIA AND SINUSITIS
Acute otitis media and acute sinusitis are most commonly
caused by S. pneumoniae, H. influenzae, or Moraxella ca-
tarrhalis.15,26'40'44,49 In acute otitis media, response to antibi-
otic therapy is often difficult to interpret due to a high rate of
spontaneous resolution.15,34
Some case reports of "standard dose" amoxicillin treatment,
failure have been reported in pneumococcal otitis media, par-
ticularly in cases with high-level penicillin resistance.19,34,49
However, it has been suggested that the administration of high
doses of amoxicillin might be effective at least in those cases
with intermediate penicillin resistance.19
Because in most cases microbiological cultures are not avail-
able, empirical antibiotic therapy should be selected to treat the
most important microorganisms. It is important to know the
prevalence of pneumococci resistant to penicillin and other an-
tibiotics, as well as the prevalence of strains of H. influenzae
and M. catarrhalis producing /3-lactamase in the patient's ge-
ographic area.
As shown in Table 4, the treatment of choice for acute oti-
tis media and acute sinusitis may be amoxicillin. In regions in
which penicillin-resistant pneumococci is prevalent, the ad-
ministration of high-dose amoxicillin may be prudent. In places
with a high percentage of H. influenzaea and M. catarrhalis
producing /3-lactamase, amoxicillin-clavulanate or cefuroxime
may be preferred.
Because of the low penetration of the antibiotics in the mid-
dle ear, otitis media caused by high-level penicillin-resistant
pneumococci may not respond to standard doses of amoxicillin
or amoxicilli-clavulanate.34 If a patient with acute otitis media
has a clinical failure after 48 hr of amoxicillin-clavulanate,
amoxicillin at 30-40 mg/kg per day may be added to obtain
higher amoxicillin dose (total 80 mg/kg per day) while not in-
creasing the total clavulanate dose.19 Other alternative drugs(e.g., ceftriaxone, macrolide, or TMP-SMZ) may also be con-
sidered. Tympanocentesis may be required in patients who do
not respond to therapy and this technique would allow the iden-
tification of the causative organism and susceptibility studies.
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